KALVISTA PHARMACEUTICALS INC. overview

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. “I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for sebetralstat, a novel, investigational treatment for hereditary angioedema (HAE). “KalVista is successfully executing on the key milestones we announced at the beginning of our fiscal year as we move towards...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares of KalVista common stock on December 2, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $10.27 per share, which was equal...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. “I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors,” said Ben Palleiko, Chief Executive Officer of KalVista. “His extensive...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT Each presentation will be live webcast on the Company’s website at www.kalvista.com . After the presentations, an audio archive will be available on KalVista’s...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the grant of an inducement award to the Company’s recently appointed Chief Commercial Officer, Nicole Sweeny. In connection with Ms. Sweeny’s appointment, the compensation committee of KalVista’s board of directors granted inducement options to purchase an aggregate of 100,000 shares of KalVista common stock on July 24, 2023 as an inducement material to Ms. Sweeny entering into employment with KalVista. The options have an...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230725517894/en/ KalVista Chief Commercial Officer Nicole Sweeny (Photo: Business Wire) “As KalVista prepares for our...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented data on the hereditary angioedema (HAE) attack journey and a patient preference study at the 2023 US HAEA National Summit in Orlando, Florida. The following presentations occurred at the HAEA Summit: In Their Own Words - Patient Descriptions of the Earliest Recognition of...